CYTEGRITY

Serial Number 98232757
730

Registration Progress

Application Filed
Oct 20, 2023
Under Examination
Mar 11, 2025
Approved for Publication
Jan 14, 2025
Published for Opposition
Jan 14, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Mar 11, 2026 82 days

Trademark Image

CYTEGRITY

Basic Information

Serial Number
98232757
Filing Date
October 20, 2023
Published for Opposition
January 14, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Aug 11, 2025
Application
Pending
Classes
001 005

Rights Holder

CSL Behring Gene Therapy, Inc.

03
Address
Suite 650
35 N. Lake Avenue
Pasadena, CA 91101

Ownership History

CSL Behring Gene Therapy, Inc.

Original Applicant
03
Pasadena, CA

CSL Behring Gene Therapy, Inc.

Owner at Publication
03
Pasadena, CA

Legal Representation

Attorney
Scott D. Woldow

USPTO Deadlines

Next Deadline
82 days remaining
NOA E-Mailed - SOU Required
Due Date
March 11, 2026
Extension Available
Until September 11, 2026

Application History

21 events
Date Code Type Description Documents
Aug 25, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 11, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 11, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 11, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 11, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 11, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 14, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 14, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 8, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 17, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 11, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 11, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 11, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 11, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Sep 11, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jun 13, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 13, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 13, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 5, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 25, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 24, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 001
Cell lines, being cells, for scientific and research use; Cells for scientific, laboratory or medical research; Biological preparations, namely, viral vectors and gene vectors for scientific, laboratory or medical research; Cell lines for clinical laboratory use; cell lines for scientific research, namely, cell lines for gene expression and for the synthesis of biological compounds; cells for scientific, laboratory, or medical research, namely, cells for gene expression systems and for the synthesis of biological compounds; viral vectors for use in science and industry
Class 005
Cell lines for medical purposes; Cells for medical or clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating cancer, tumors, genetic diseases, immunodeficiency conditions, stem cell transplantation, and transplant medicine; Biological preparations, namely, viral vectors and gene therapy vectors for therapeutic use and clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for treating a wide range of diseases, illnesses or conditions; Cell lines for medical purposes, namely, cell therapy; Cell lines for medical purposes, namely, immunotherapy; Cell lines for medical purposes, namely, for use as therapeutics to repair, replace or preserve cells and tissues; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating genetically engineered tissues and for treating transplant conditions; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating viral and infectious diseases; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders; viral vectors for medical use relating to gene therapy; gene therapy vectors for medical use

Classification

International Classes
001 005